MRK·Merck & Co., Inc.

Merck's growth story is being shaped by recent strategic moves. Health Canada's approval of KEYTRUDA SC, the subcutaneous formulation of its cancer therapy, expands treatment options. This is further bolstered by a new AI-focused drug discovery partnership with the Mayo Clinic, aiming to revolutionize drug discovery processes. This collaboration will leverage Mayo Clinic's clinical data and platform with Merck's AI capabilities, potentially improving disease understanding and accelerating drug development. These developments, coupled with strong Keytruda sales and positive clinical trial results, suggest continued momentum in the oncology segment. A recent report also highlights Merck as a key player in the cancer vaccine market, suggesting potential implications for its strategic positioning. Investors should watch for further developments in partnerships and clinical trial outcomes. Additionally, Merck offers a compelling dividend opportunity, supported by strong profitability and a history of increasing dividends.